Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 13, 2024 07:00 ET | Source: MiNK Therapeutics

MiNK Reports Second Quarter 2024 Results and Business Update

Expanded Access to AgenT-797 in Severe ARDS Reinforces Clinical Efficacy; Data Highlighted at ATS 2024 Annual MeetingPhase 2 Study in 2L Gastric Cancer Advances; Early Clinical Data to be Presented at...
August 01, 2024 07:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report

NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...
July 31, 2024 07:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement

NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...
June 05, 2024 07:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...
May 22, 2024 07:30 ET | Source: MiNK Therapeutics

MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...
May 14, 2024 07:30 ET | Source: MiNK Therapeutics

MiNK Reports First Quarter 2024 Results

Completed $5.8 million private placement financing at 25% premium Upcoming presentation of agenT-797 in severe respiratory distress at the American Thoracic Society (ATS)AACR presentation reported...
May 13, 2024 07:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer

Financing of $5.8 Million at a 25% premium will help advance the clinical development of MiNK-215, an armored-FAP-CAR-iNKTGKCC, LLC joins as a new investor with Katie Chudnovsky appointed as a Board...
April 30, 2024 07:30 ET | Source: MiNK Therapeutics

MiNK to Provide Corporate Update and First Quarter 2024 Financial Report

NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...
April 08, 2024 12:00 ET | Source: MiNK Therapeutics

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid modelsMiNK-215 exhibits potent anti-tumor activity through multiple mechanisms including immune activation NEW YORK, April...
March 21, 2024 07:00 ET | Source: MiNK Therapeutics

MiNK Reports Fourth Quarter and Year-End 2023 Results

Launched and enrolling Phase 2 trial of allo-iNKTs with botensilimab/balstilimab and chemotherapy in second-line gastroesophageal cancers Announced collaboration with Immunoscape for development of...